EpiCypher Launches Fiber-seq, a Breakthrough Multiomic Single-Molecule Genomics Assay

Quotient Sciences and CPI to Accelerate RNA Drug Development with Joint Venture

PhenoTips Receives the Life Sciences Innovation Fund: The Ontario-based life sciences company was awarded $500,000 by the Ontario Centre of Innovation to support growth in the precision medicine marketplace

PhenoTips, based in Toronto, has developed a first-of-its-kind cloud-based software that streamlines and digitizes genomic health record management, saving clinicians time and supporting precision medicine initiatives. In June 2025, PhenoTips was one of 13 Ontario-based life sciences companies to receive the renewed Life Sciences Innovation Fund from the government of Ontario, through the Ontario Centre of Innovation (OCI).

Ametris expands collaborative research project to investigate digital measures of physical function for drug development in obesity

Ametris (formerly ActiGraph), a global digital health solutions provider transforming real-world patient data into validated clinical evidence, announced the launch of Digital Endpoint Collaboration to accelerate Outcome DEvelopment (DECODE) in Obesity.

CN Bio adds computational modeling capabilities to ADME services for enhanced bioavailability profiling

• New PhysioMimix in silico tools unlock deeper functional insights from existing assays, advancing translation of MPS data to predict human ADME behavior • End-to-end support from experimental design to data interpretation

Aptamer Group Introduces Novel Biomarker Discovery Service

Qureight’s AI 3D imaging platform to support Calluna Pharma’s Phase 2 AURORA study of CAL101 in Idiopathic Pulmonary Fibrosis (IPF)

• Qureight’s advanced AI 3D imaging platform to be used across clinical trial to evaluate anatomical lung changes in adult patients, including during patient enrolment • CAL101 is a first-in-class monoclonal antibody that neutralises the S100A4 protein, which is an upstream driver and amplifier of the multiple pro-fibrotic pathways active in IPF

Advancing regenerative medicine: Cellbricks Therapeutics reaches key milestone using Rousselot biomaterials

Rousselot announces promising preclinical results from a study conducted by Cellbricks Therapeutics, a Berlin-based biotech startup and spin-off from the Technical University of Berlin. As a pioneer in 3D-bioprinting, Cellbricks successfully implanted 3D-bioprinted adipose tissue constructs into mice, with no signs of fibrosis or rejection observed after seven weeks.

Hongene to supply exNA oligonucleotide technology under new licensing deal

DNAnexus Enhances Leadership to Fuel AI Innovation and Biopharma Expansion

Company appoints Pieter De Leenheer as Chief Technology Officer and Todd Oakland as Senior Vice President and General Manager of Biopharma Business Dx/Rx

Huateng Pharma Expands Cosmetic Ingredients Portfolio with Reliable, Ready-to-Ship Actives

Huateng Pharma offers reliable cosmetic ingredients including Diethylamino Hydroxybenzoyl Hexyl Benzoate, Tetrahydrocurcumin, and Piroctone Olamine.

eClinical Solutions Announces Integrated Data Review Plan (IDRP) Capabilities Within elluminate Platform

Company becomes the first to centralize digital data review activities within a single platform as the industry focuses on clinical trial efficiency

ZeOmega Launches Smart Auth Optimizer to Transform Prior Authorization

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

Friends of Cancer Research and MMS Collaborate to Develop Decision Frameworks for Interim Overall Survival Data in Oncology Trials

MMS, a global has announced that it has been chosen by Friends of Cancer Research to support the development of practical decision frameworks to inform the interpretation of interim overall survival data in oncology clinical trials.

Ambience Healthcare Joins Epic Toolbox, Unlocking Advanced AI Functionality Within Haiku for Epic Customers

TetraScience Launches Tetra Workflows to Automate Scientific Data Workflows at Scale

Tetra Workflows enables laboratories to orchestrate and automate data workflows from instruments to lab informatics software at unprecedented scale and reliability. The platform encompasses the entire journey of scientific data, from initial collection and input through storage, analysis, and reporting, ensuring data quality, reliability, consistency, traceability, and efficiency throughout the process.

Transforming Parkinson’s Disease Treatment , Insilico Medicine Announces IND-enabling Completion for AI-empowered Oral NLRP3 Inhibitor ISM8969

Insilico Medicine has completed IND-enabling studies for ISM8969 the oral NLRP3 inhibitor, and plans to submit the Investigational New Drug (IND) application in the fourth quarter of 2025 to begin clinical validation. Based on the potential of ISM8969 against neurodegenerative disorders, as demonstrated in pre-clinical studies, the drug candidate will be evaluated as a novel option for Parkinson’s disease (PD) treatment. Empowered by Insilico Medicine’s Pharma.AI platform, ISM8969 demonstrated favorable PD/PK profiles, as well as dose-dependent efficacy in motor functions in animal models.

ZeOmega and Clearlink Partners Unite to Streamline Delegated Clinical Services

Cotiviti Welcomes Veteran Healthcare Technology Growth Leader Robert Kopanic as Chief Revenue Officer